Study uncovers distinct blood protein signature in children with Long COVID

Distinct protein profiles linked to inflammation and angiogenesis found in children with Long COVID, paving the way for improved diagnostics and therapies.

Novel Glucagon/GLP-1 Receptor Dual Agonist Improved MASH in Phase II Study

Survodutide, a novel glucagon/GLP-1 receptor dual agonist, improved metabolic dysfunction-associated steatohepatitis (MASH) with no worsening of fibrosis, according to results of a phase II trial.

June 8, 2024

Cardiovascular burden of TTR gene variant among Black carriers across mid to late-life

The key contribution of this study was to provide more accurate estimates of cardiovascular risk across mid to late life, compared to previously existing analyses.

May 15, 2024

4 takeaways from Stryker’s investor day

Stryker shared long-term financial goals at its investor day on Wednesday. The company expects to outpace the market in revenue growth and return to pre-pandemic

November 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.